These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 10498620)

  • 1. In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells.
    Mahgoub N; Taylor BR; Gratiot M; Kohl NE; Gibbs JB; Jacks T; Shannon KM
    Blood; 1999 Oct; 94(7):2469-76. PubMed ID: 10498620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors.
    Emanuel PD; Snyder RC; Wiley T; Gopurala B; Castleberry RP
    Blood; 2000 Jan; 95(2):639-45. PubMed ID: 10627474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines.
    Zhang YY; Vik TA; Ryder JW; Srour EF; Jacks T; Shannon K; Clapp DW
    J Exp Med; 1998 Jun; 187(11):1893-902. PubMed ID: 9607929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nf1 and Gmcsf interact in myeloid leukemogenesis.
    Birnbaum RA; O'Marcaigh A; Wardak Z; Zhang YY; Dranoff G; Jacks T; Clapp DW; Shannon KM
    Mol Cell; 2000 Jan; 5(1):189-95. PubMed ID: 10678181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia.
    Largaespada DA; Brannan CI; Jenkins NA; Copeland NG
    Nat Genet; 1996 Feb; 12(2):137-43. PubMed ID: 8563750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia.
    Mesa RA; Tefferi A; Gray LA; Reeder T; Schroeder G; Kaufmann SH
    Leukemia; 2003 May; 17(5):849-55. PubMed ID: 12750696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
    Yan N; Ricca C; Fletcher J; Glover T; Seizinger BR; Manne V
    Cancer Res; 1995 Aug; 55(16):3569-75. PubMed ID: 7627966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.
    Bollag G; Clapp DW; Shih S; Adler F; Zhang YY; Thompson P; Lange BJ; Freedman MH; McCormick F; Jacks T; Shannon K
    Nat Genet; 1996 Feb; 12(2):144-8. PubMed ID: 8563751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
    Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
    Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
    Peters DG; Hoover RR; Gerlach MJ; Koh EY; Zhang H; Choe K; Kirschmeier P; Bishop WR; Daley GQ
    Blood; 2001 Mar; 97(5):1404-12. PubMed ID: 11222387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farnesyltransferase inhibitor FTI-277 prevents autocrine growth stimulation of neuroblastoma by BDNF.
    Girgert R; Wittrock J; Pfister S; Schweizer P
    J Cancer Res Clin Oncol; 2003 Apr; 129(4):227-33. PubMed ID: 12700894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
    Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines.
    Mazzocca A; Giusti S; Hamilton AD; Sebti SM; Pantaleo P; Carloni V
    Mol Pharmacol; 2003 Jan; 63(1):159-66. PubMed ID: 12488548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors.
    Fiordalisi JJ; Johnson RL; Weinbaum CA; Sakabe K; Chen Z; Casey PJ; Cox AD
    J Biol Chem; 2003 Oct; 278(43):41718-27. PubMed ID: 12882980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway.
    Law BK; Nørgaard P; Gnudi L; Kahn BB; Poulson HS; Moses HL
    J Biol Chem; 1999 Feb; 274(8):4743-8. PubMed ID: 9988711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukemic potential of doubly mutant Nf1 and Wv hematopoietic cells.
    Ingram DA; Wenning MJ; Shannon K; Clapp DW
    Blood; 2003 Mar; 101(5):1984-6. PubMed ID: 12393498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.
    Bolick SC; Landowski TH; Boulware D; Oshiro MM; Ohkanda J; Hamilton AD; Sebti SM; Dalton WS
    Leukemia; 2003 Feb; 17(2):451-7. PubMed ID: 12592346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors.
    Morgan MA; Wegner J; Aydilek E; Ganser A; Reuter CW
    Leukemia; 2003 Aug; 17(8):1508-20. PubMed ID: 12886237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.